SGLT2 Inhibitors Lower NAFLD, HCC Risks Over DPP4i SGLT2 Inhibitors Lower NAFLD, HCC Risks Over DPP4i

Sodium glucose cotransporter 2 inhibitors (SGLT2is) lowered the risk of nonalcoholic fatty liver disease and hapatocellular carcinoma versus dipeptidyl-peptidase-4 inhibitors (DPP4is).First Look
Source: Medscape Diabetes Headlines - Category: Endocrinology Tags: Diabetes & Endocrinology News Source Type: news